Publication | Closed Access
Direct <i>N</i>–SF<sub>5</sub> and <i>N</i>–SF<sub>4</sub>CF<sub>3</sub> Bond Formation through Strain-Release Functionalization of 3-Substituted [1.1.0]Azabicyclobutanes
12
Citations
85
References
2025
Year
In comparison to modern methods for carbon-SF<sub>5</sub> bond formation, methods for <i>direct heteroatom-SF</i><sub>5</sub> <i>bond formation</i> are exceptionally scarce, rendering motifs such as "<i>N</i>-SF<sub>5</sub>" virtually unexplored in the context of organic and medicinal chemistry. Herein, we demonstrate that direct <i>N</i>-SF<sub>5</sub> bond formation can be accomplished through strain-release pentafluorosulfanylation of 3-aryl [1.1.0]azabicyclobutanes (ABBs), using an easy-to-access solution of SF<sub>5</sub>Cl. To our surprise, the resultant <i>N</i>-SF<sub>5</sub> azetidines proved to be remarkably chemically stable and amenable to peripheral synthetic modifications (e.g., amination, cross-coupling, oxidation, dehalogenation, S<sub>N</sub>1, and S<sub>N</sub>Ar reactions). The methodology also extends to direct <i>N</i>-SF<sub>4</sub>CF<sub>3</sub> bond formation using <i>trans</i>-CF<sub>3</sub>SF<sub>4</sub>Cl, enabling comparative studies throughout this work. From a mechanistic standpoint, DFT calculations, Hammett analyses, and radical trapping experiments support our proposed radical chain propagation mechanism. From a fundamental standpoint, considering <i>N</i>-SF<sub>5</sub> and <i>N</i>-SF<sub>4</sub>CF<sub>3</sub> azetidines are heretofore unknown molecular motifs, this work analyzes their dynamic, spectroscopic, and crystallographic features, as well as computed properties (e.g., BDE and p<i>K</i><sub>b</sub> values), to provide foundational knowledge and inform downstream applications. While the carbon-bound SF<sub>5</sub> group has been employed as a bioisostere for a CF<sub>3</sub> group, we posited the <i>N</i>-SF<sub>5</sub> motif could be a potential replacement for a small sulfonamide. Accordingly, we synthesized an <i>N</i>-SF<sub>5</sub> derivative of a spleen tyrosine kinase inhibitor reported in the patent literature for comparative ADME studies; results from <i>in vitro</i> profiling indicate that an <i>N</i>-SF<sub>5</sub> azetidine could indeed be an alternative for an <i>N</i>-SO<sub>2</sub>Me azetidine, in cases where enhanced lipophilicity is desirable.
| Year | Citations | |
|---|---|---|
Page 1
Page 1